Literature DB >> 8302362

Comparative efficacy of amphotericin B, clotrimazole and itraconazole against Aspergillus spp. An in vitro study.

Y H Hahn1, D G Ahearn, L A Wilson.   

Abstract

The susceptibilities of two isolates of Aspergillus flavus, one from a human case of recalcitrant mycotic keratitis, and an environmental isolate of A. fumigatus, to itraconazole, clotrimazole and amphotericin B were measured. Observations of macroscopic growth and microscopic evaluations of conidia germination both indicated that the two isolates of A. flavus were markedly more resistant to amphotericin B than to itraconazole and clotrimazole. Itraconazole was more effective than clotrimazole for all isolates. Our in vitro susceptibility results suggest the use of itraconazole should be a primary consideration in the treatment of Aspergillus keratitis.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8302362     DOI： 10.1007/BF01111263

Source DB:  PubMed          Journal:  Mycopathologia        ISSN： 0301-486X            Impact factor:   2.574


  18 in total

1.  Fungus keratitis (Aspergillus fumigatus); treatment with nystain (mycostatin).

Authors:  A B MANGIARACINE; S D LIEBMAN
Journal:  AMA Arch Ophthalmol       Date:  1957-11

2.  Aspergillus flavus keratitis.

Authors:  G N Chin; N L Goodman
Journal:  Ann Ophthalmol       Date:  1978-04

3.  Improved method for estimation of azole antifungal inhibitory concentrations against Candida species, based on azole/antibiotic interactions.

Authors:  F C Odds; A B Abbott; G Pye; P F Troke
Journal:  J Med Vet Mycol       Date:  1986-08

4.  Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results.

Authors:  B Dupont; E Drouhet
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb

5.  MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp.

Authors:  H J Schmitt; E M Bernard; J Andrade; F Edwards; B Schmitt; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

6.  Itraconazole, a new triazole that is orally active in aspergillosis.

Authors:  J Van Cutsem; F Van Gerven; M A Van de Ven; M Borgers; P A Janssen
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

7.  Itraconazole therapy for fungal keratitis.

Authors:  J Rajasekaran; P A Thomas; C M Kalavathy; P C Joseph; D J Abraham
Journal:  Indian J Ophthalmol       Date:  1987       Impact factor: 1.848

8.  Spectrum of microbial keratitis in South Florida.

Authors:  T J Liesegang; R K Forster
Journal:  Am J Ophthalmol       Date:  1980-07       Impact factor: 5.258

9.  Miconazole therapy for keratomycosis.

Authors:  C S Foster
Journal:  Am J Ophthalmol       Date:  1981-05       Impact factor: 5.258

Review 10.  Oral and parenteral treatment with itraconazole in various superficial and systemic experimental fungal infections. Comparisons with other antifungals and combination therapy.

Authors:  J Van Cutsem
Journal:  Br J Clin Pract Suppl       Date:  1990-09
View more
  2 in total

1.  Antifungal activity of a liposomal itraconazole formulation in experimental Aspergillus flavus keratitis with endophthalmitis.

Authors:  André Ferraz Goiana Leal; Melyna Chaves Leite; Caroline Sanuzi Quirino Medeiros; Isabella Macário Ferro Cavalcanti; Almir Gonçalves Wanderley; Nereide Stela Santos Magalhães; Rejane Pereira Neves
Journal:  Mycopathologia       Date:  2014-11-28       Impact factor: 2.574

2.  Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay.

Authors:  B Jahn; E Martin; A Stueben; S Bhakdi
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.